NCT05736939

Brief Summary

The goal of this retrospective analysis is to compare the magnitude of improvement in respiratory and peripheral muscle strength, following the completion of a hybrid pulmonary rehabilitation programme, in men and women with long COVID-19 syndrome. The main question it aims to answer is the following: • does gender limits the effects of a hybrid pulmonary rehabilitation programme on respiratory and peripheral muscle strength?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2022

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

February 19, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 21, 2023

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2023

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2023

Completed
Last Updated

October 11, 2023

Status Verified

October 1, 2023

Enrollment Period

5 months

First QC Date

February 19, 2023

Last Update Submit

October 7, 2023

Conditions

Keywords

Post-Acute COVID-19 SyndromePulmonary RehabilitationMuscle strengthQuality of life

Outcome Measures

Primary Outcomes (1)

  • Fatigue

    Degree of fatigue will be assessed via the Functional Assessment of Chronic Illness Therapy questionnaire

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

Secondary Outcomes (14)

  • Quadriceps muscle strength

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

  • Handgrip muscle strength

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

  • Inspiratory muscle strength

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

  • Expiratory muscle strength

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

  • Dyspnoea

    Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)

  • +9 more secondary outcomes

Study Arms (2)

Men with long COVID-19 syndrome

Patients were male adults (\>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.

Other: Out-patient Pulmonary Rehabilitation

Women with long COVID-19 syndrome

Patients were women adults (\>18 years), with persistent symptoms more than 3 months since the acute phase of the COVID-19.

Other: Out-patient Pulmonary Rehabilitation

Interventions

Pulmonary Rehabilitation (PR) programme consisting of 30 minutes interval aerobic exercise on cycle ergometers at 100% of peak work rate (WRpeak) and resistance exercises for the upper body. Dyspnoea and leg discomfort were recorded on the modified 1-10 Borg scale, whereas heart rate (HR) and oxygen saturation (SpO2%) were monitored by a pulse oximeter. Based on symptoms of breathlessness and fatigue reported at the end of each session, the exercise intensity was increased by 5-10% of the baseline WRpeak in the next session. The remote 24 home-based PR sessions consisted of 30 minutes walking with an individualised target of steps, recorded via the mobile app installed in the patients' mobile phone. The steps, leg discomfort and dyspnoea were reported by the patient via a physical activity diary on a weekly basis. If dyspnoea and fatigue were both \<4 at the Borg scale the weekly target of steps was increased by 5-10% by the assessors.

Men with long COVID-19 syndromeWomen with long COVID-19 syndrome

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Τhe study population consists of patients who have been diagnosed with long COVID-19 based on the persistence of fatigue at least three months following hospital discharge due to COVID-19. All patients participated in a pulmonary rehabilitation programme which is provided in these patients by our clinic.

You may qualify if:

  • Hospitalisation due to Sars-COV-2 infection.
  • Presence of persistence fatigue assessed via FACIT questionnaire.

You may not qualify if:

  • participation in another clinical trial
  • occurrence of myocardial infarction
  • hospitalisation for unstable angina
  • stroke
  • coronary artery bypass graft (CABG)
  • percutaneous coronary intervention (PCI)
  • implantation of a cardiac resynchronisation therapy device (CRTD)
  • active treatment for cancer or other malignant disease
  • uncontrolled congestive heart disease (NYHA class \>3)
  • acute psychosis or major psychiatric disorders or continued substance abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sotiria Hospital

Athens, Greece

Location

Related Publications (25)

  • Goertz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S, Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van 't Hul AJ, Janssen DJA, Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020 Oct 26;6(4):00542-2020. doi: 10.1183/23120541.00542-2020. eCollection 2020 Oct.

    PMID: 33257910BACKGROUND
  • Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.

    PMID: 32644129BACKGROUND
  • Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, Elneima O, Docherty AB, Lone NI, Leavy OC, Daines L, Baillie JK, Brown JS, Chalder T, De Soyza A, Diar Bakerly N, Easom N, Geddes JR, Greening NJ, Hart N, Heaney LG, Heller S, Howard L, Hurst JR, Jacob J, Jenkins RG, Jolley C, Kerr S, Kon OM, Lewis K, Lord JM, McCann GP, Neubauer S, Openshaw PJM, Parekh D, Pfeffer P, Rahman NM, Raman B, Richardson M, Rowland M, Semple MG, Shah AM, Singh SJ, Sheikh A, Thomas D, Toshner M, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Wain LV, Brightling CE; PHOSP-COVID Collaborative Group. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021 Nov;9(11):1275-1287. doi: 10.1016/S2213-2600(21)00383-0. Epub 2021 Oct 7.

    PMID: 34627560BACKGROUND
  • PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022 Aug;10(8):761-775. doi: 10.1016/S2213-2600(22)00127-8. Epub 2022 Apr 23.

    PMID: 35472304BACKGROUND
  • Wynberg E, van Willigen HDG, Dijkstra M, Boyd A, Kootstra NA, van den Aardweg JG, van Gils MJ, Matser A, de Wit MR, Leenstra T, de Bree G, de Jong MD, Prins M; RECoVERED Study Group. Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clin Infect Dis. 2022 Aug 24;75(1):e482-e490. doi: 10.1093/cid/ciab759.

    PMID: 34473245BACKGROUND
  • Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G, Bowyer RCE, Northstone K, Hou B, Green MJ, Dodgeon B, Doores KJ, Duncan EL, Williams FMK; OpenSAFELY Collaborative; Steptoe A, Porteous DJ, McEachan RRC, Tomlinson L, Goldacre B, Patalay P, Ploubidis GB, Katikireddi SV, Tilling K, Rentsch CT, Timpson NJ, Chaturvedi N, Steves CJ. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022 Jun 28;13(1):3528. doi: 10.1038/s41467-022-30836-0.

    PMID: 35764621BACKGROUND
  • Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Capriotti V, D'Alessandro A, Zanelli E, Marzolino R, Lazzarin C, Antonucci P, Sacchet E, Tofanelli M, Borsetto D, Gardenal N, Pengo M, Tirelli G. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021 Dec;11(12):1685-1688. doi: 10.1002/alr.22832. Epub 2021 Jun 9. No abstract available.

    PMID: 34109765BACKGROUND
  • Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, Molteni E, Modat M, Jorge Cardoso M, May A, Ganesh S, Davies R, Nguyen LH, Drew DA, Astley CM, Joshi AD, Merino J, Tsereteli N, Fall T, Gomez MF, Duncan EL, Menni C, Williams FMK, Franks PW, Chan AT, Wolf J, Ourselin S, Spector T, Steves CJ. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-631. doi: 10.1038/s41591-021-01292-y. Epub 2021 Mar 10.

    PMID: 33692530BACKGROUND
  • Lindahl A, Aro M, Reijula J, Makela MJ, Ollgren J, Puolanne M, Jarvinen A, Vasankari T. Women report more symptoms and impaired quality of life: a survey of Finnish COVID-19 survivors. Infect Dis (Lond). 2022 Jan;54(1):53-62. doi: 10.1080/23744235.2021.1965210. Epub 2021 Aug 19.

    PMID: 34410220BACKGROUND
  • Fernandez-de-Las-Penas C, Martin-Guerrero JD, Pellicer-Valero OJ, Navarro-Pardo E, Gomez-Mayordomo V, Cuadrado ML, Arias-Navalon JA, Cigaran-Mendez M, Hernandez-Barrera V, Arendt-Nielsen L. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J Clin Med. 2022 Jan 14;11(2):413. doi: 10.3390/jcm11020413.

    PMID: 35054108BACKGROUND
  • Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.

    PMID: 33442016BACKGROUND
  • Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force. Eur Respir J. 2020 Dec 3;56(6):2002197. doi: 10.1183/13993003.02197-2020. Print 2020 Dec.

    PMID: 32817258BACKGROUND
  • Singh SJ, Barradell AC, Greening NJ, Bolton C, Jenkins G, Preston L, Hurst JR. British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. BMJ Open. 2020 Dec 2;10(12):e040213. doi: 10.1136/bmjopen-2020-040213.

    PMID: 33268418BACKGROUND
  • Fugazzaro S, Contri A, Esseroukh O, Kaleci S, Croci S, Massari M, Facciolongo NC, Besutti G, Iori M, Salvarani C, Costi S; Reggio Emilia COVID-19 Working Group. Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. Int J Environ Res Public Health. 2022 Apr 24;19(9):5185. doi: 10.3390/ijerph19095185.

    PMID: 35564579BACKGROUND
  • Spielmanns M, Buelow MM, Pekacka-Egli AM, Cecon M, Spielmanns S, Windisch W, Hermann M. Clinical and Functional Predictors of Response to a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients. Microorganisms. 2021 Nov 28;9(12):2452. doi: 10.3390/microorganisms9122452.

    PMID: 34946054BACKGROUND
  • Kolodziej M, Wyszynska J, Bal-Bochenska M. COVID-19: A New Challenge for Pulmonary Rehabilitation? J Clin Med. 2021 Jul 29;10(15):3361. doi: 10.3390/jcm10153361.

    PMID: 34362142BACKGROUND
  • Dalbosco-Salas M, Torres-Castro R, Rojas Leyton A, Morales Zapata F, Henriquez Salazar E, Espinoza Bastias G, Beltran Diaz ME, Tapia Allers K, Mornhinweg Fonseca D, Vilaro J. Effectiveness of a Primary Care Telerehabilitation Program for Post-COVID-19 Patients: A Feasibility Study. J Clin Med. 2021 Sep 27;10(19):4428. doi: 10.3390/jcm10194428.

    PMID: 34640447BACKGROUND
  • D'Angelo E, Prandi E, Marazzini L, Milic-Emili J. Dependence of maximal flow-volume curves on time course of preceding inspiration in patients with chronic obstruction pulmonary disease. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1581-6. doi: 10.1164/ajrccm.150.6.7952618.

    PMID: 7952618BACKGROUND
  • Koulouris N, Mulvey DA, Laroche CM, Green M, Moxham J. Comparison of two different mouthpieces for the measurement of Pimax and Pemax in normal and weak subjects. Eur Respir J. 1988 Oct;1(9):863-7.

    PMID: 3229485BACKGROUND
  • Ringqvist T. The ventilatory capacity in healthy subjects. An analysis of causal factors with special reference to the respiratory forces. Scand J Clin Lab Invest Suppl. 1966;88:5-179. No abstract available.

    PMID: 4283858BACKGROUND
  • Darling RC, Cournand A, Richards DW. STUDIES ON THE INTRAPULMONARY MIXTURE OF GASES. III. AN OPEN CIRCUIT METHOD FOR MEASURING RESIDUAL AIR. J Clin Invest. 1940 Jul;19(4):609-18. doi: 10.1172/JCI101163. No abstract available.

    PMID: 16694777BACKGROUND
  • Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005 Oct;26(4):720-35. doi: 10.1183/09031936.05.00034905. No abstract available.

    PMID: 16204605BACKGROUND
  • Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:1-100. No abstract available.

    PMID: 8499052BACKGROUND
  • Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81.

    PMID: 7154893BACKGROUND
  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.

    PMID: 12091180BACKGROUND

Related Links

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

COVID-19Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Nikolaos Chynkiamis, Ph.D.

    Sotiria General Hospital for Chest Diseases, Athens, Greece

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Exercise Physiologist

Study Record Dates

First Submitted

February 19, 2023

First Posted

February 21, 2023

Study Start

October 1, 2022

Primary Completion

February 28, 2023

Study Completion

March 15, 2023

Last Updated

October 11, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

The individual participant data will not be shared to any other research team. The data that will be collected retrospectively for the present study as the patients have already completed the pulmonary rehabilitation programme. The rehabilitation department of our clinic is responsible for the storage and the management of patients data. In that content, they will share with the research team the necessary data to complete our study. The research team is not authorised to share the data with other research teams or researchers.

Locations